Item 8.01 Other Events.
On October 15, 2020, Sage Therapeutics, Inc. (the "Company") issued a press
release announcing interim, topline data from the Company's ongoing Phase 3
open-label SHORELINE study evaluating zuranolone (SAGE-217) in the treatment of
patients with major depressive disorder. A copy of the press release is filed as
Exhibit 99.1 hereto and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by Sage Therapeutics, Inc. on October 15, 2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses